306 related articles for article (PubMed ID: 26056018)
1. Severe hypercalcemia following denosumab treatment in a juvenile patient.
Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
[TBL] [Abstract][Full Text] [Related]
2. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
[TBL] [Abstract][Full Text] [Related]
4. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
Wang R; Renouf DA
Osteoporos Int; 2022 Jul; 33(7):1625-1629. PubMed ID: 35286436
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia after discontinuation of long-term denosumab treatment.
Koldkjær Sølling AS; Harsløf T; Kaal A; Rejnmark L; Langdahl B
Osteoporos Int; 2016 Jul; 27(7):2383-2386. PubMed ID: 27098536
[TBL] [Abstract][Full Text] [Related]
6. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
Boyce AM
Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
[TBL] [Abstract][Full Text] [Related]
7. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcemia in Children Following a Discontinuation of Denosumab Therapy: A Case Report and Literature Review.
Liu X; Xie Y; Tang J; Zhong J; Lan D
Clin Pediatr (Phila); 2024 Jun; 63(6):750-754. PubMed ID: 37594083
[No Abstract] [Full Text] [Related]
10. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI.
Trejo P; Rauch F; Ward L
J Musculoskelet Neuronal Interact; 2018 Mar; 18(1):76-80. PubMed ID: 29504582
[TBL] [Abstract][Full Text] [Related]
11. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
12. Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report.
Del Sindaco G; Berlanga P; Brugières L; Thebault E; Mantovani G; Wicart P; Linglart A
Front Endocrinol (Lausanne); 2021; 12():698963. PubMed ID: 34335473
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report.
Maugars Y; Guillot P; Glémarec J; Berthelot JM; Le Goff B; Darrieutort-Laffite C
J Med Case Rep; 2020 Aug; 14(1):130. PubMed ID: 32792004
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
15. Aneurysmal bone cyst: results of an off label treatment with Denosumab.
Dürr HR; Grahneis F; Baur-Melnyk A; Knösel T; Birkenmaier C; Jansson V; Klein A
BMC Musculoskelet Disord; 2019 Oct; 20(1):456. PubMed ID: 31630689
[TBL] [Abstract][Full Text] [Related]
16. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
Nasser SM; Sahal A; Hamad A; Elazzazy S
J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
[TBL] [Abstract][Full Text] [Related]
17. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
18. Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report.
Park MJ; Ganjoo KN; Ladd AL
J Hand Surg Am; 2015 Aug; 40(8):1620-4. PubMed ID: 25935517
[TBL] [Abstract][Full Text] [Related]
19. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
20. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]